title: [Efficacy of omalizumab in patients with severe asthma using the asthma health questionnaire and asthma control test].
abstract: BACKGROUND
  The efficacy of anti-IgE antibody, omalizumab, was studied in patients with severe bronchial asthma. There have been reports stating that although omalizumab could not improve objective results, it has shown improvements in subjective symptoms of patients. The aim of this study is to evaluate the efficacy of omalizumab in severe bronchial asthma.
  
  
  METHODS
  Thirteen patients were enrolled. Omalizumab was administered subcutaneously every 2 or 4 weeks based on serum IgE level and body weight of each patient. Pulmonary function tests, Asthma Control Test (ACT), Asthma Health Questionnaire-JAPAN (AHQ-JAPAN), number of emergency visits and dosage of methylprednisolone during a 16-week period were compared to the previous year. We examined the correlations between respiratory function, and ACT and AHQ-JAPAN.
  
  
  RESULTS
  Treatment with omalizumab did not improve lung function. AHQ and ACT over the 16-week period significantly improved compared to baseline (p<0.01). The number of emergency visit and doses of methylprednisolone were significantly reduced compared to the previous year (p<0.01).
  
  
  CONCLUSIONS
  Although treatment with omalizumab could not improve lung function, AHQ and ACT during the 16-week study period had significantly improved compared to baseline. Omalizumab significantly reduced the number of emergency visits and dosages of methylprednisolone.
authors: Division of Respiratory Diseases, Department of Internal Medicine, Kawasaki Municipal Tama Hospital.
authors: Junko
authors: J
authors: Saji
authors: Division of Respiratory Diseases, Department of Internal Medicine, Kawasaki Municipal Tama Hospital.
authors: Motonaka
authors: M
authors: Arai
authors: Division of Respiratory Diseases, Department of Internal Medicine, Kawasaki Municipal Tama Hospital.
authors: Takahito
authors: T
authors: Yamamoto
authors: Division of Respiratory and Infectious Diseases, Department of Internal Medicine, St. Marianna University School of Medicine.
authors: Masamichi
authors: M
authors: Mineshita
authors: Division of Respiratory and Infectious Diseases, Department of Internal Medicine, St. Marianna University School of Medicine.
authors: Teruomi
authors: T
authors: Miyazawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab